State Street’s Sinovac Biotech, Ltd SVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-160,875
| Closed | -$1.04M | – | 4468 |
|
|
2024
Q1 | $1.04M | Buy |
+160,875
| New | +$1.04M | ﹤0.01% | 3461 |
|
|
2023
Q4 | – | Sell |
-160,875
| Closed | -$1.04M | – | 4600 |
|
|
2023
Q3 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3521 |
|
|
2023
Q2 | $1.04M | Buy |
+160,875
| New | +$1.04M | ﹤0.01% | 3575 |
|
|
2022
Q4 | – | Sell |
-160,875
| Closed | -$1.04M | – | 5006 |
|
|
2022
Q3 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3593 |
|
|
2022
Q2 | $1.04M | Buy |
+160,875
| New | +$1.04M | ﹤0.01% | 3624 |
|
|
2022
Q1 | – | Sell |
-281,640
| Closed | -$1.82M | – | 4996 |
|
|
2021
Q4 | $1.82M | Hold |
281,640
| – | – | ﹤0.01% | 3664 |
|
|
2021
Q3 | $1.82M | Hold |
281,640
| – | – | ﹤0.01% | 3638 |
|
|
2021
Q2 | $1.82M | Hold |
281,640
| – | – | ﹤0.01% | 3563 |
|
|
2021
Q1 | $1.82M | Buy |
281,640
+120,765
| +75% | +$781K | ﹤0.01% | 3473 |
|
|
2020
Q4 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3550 |
|
|
2020
Q3 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3418 |
|
|
2020
Q2 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3411 |
|
|
2020
Q1 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3296 |
|
|
2019
Q4 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3396 |
|
|
2019
Q3 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3386 |
|
|
2019
Q2 | $1.04M | Hold |
160,875
| – | – | ﹤0.01% | 3414 |
|
|
2019
Q1 | $1.04M | Buy |
160,875
+19,363
| +14% | +$127K | ﹤0.01% | 3330 |
|
|
2018
Q4 | $982K | Buy |
141,512
+18,791
| +15% | +$137K | ﹤0.01% | 3331 |
|
|
2018
Q3 | $943K | Sell |
122,721
-11,402
| -9% | -$82.3K | ﹤0.01% | 3413 |
|
|
2018
Q2 | $1M | Sell |
134,123
-2,046
| -2% | -$16.1K | ﹤0.01% | 3406 |
|
|
2018
Q1 | $1.17M | Buy |
136,169
+47,915
| +54% | +$395K | ﹤0.01% | 3316 |
|
|
2017
Q4 | $695K | Buy |
88,254
+9,918
| +13% | +$74.2K | ﹤0.01% | 3407 |
|
|
2017
Q3 | $552K | Buy |
78,336
+29,055
| +59% | +$198K | ﹤0.01% | 3459 |
|
|
2017
Q2 | $333K | Buy |
49,281
+7,711
| +19% | +$42.3K | ﹤0.01% | 3481 |
|
|
2017
Q1 | $237K | Sell |
41,570
-755
| -2% | -$4.37K | ﹤0.01% | 3486 |
|
|
2016
Q4 | $250K | Buy |
42,325
+5,607
| +15% | +$33.7K | ﹤0.01% | 3476 |
|
|
2016
Q3 | $216K | Buy |
36,718
+19,806
| +117% | +$116K | ﹤0.01% | 3393 |
|
|
2016
Q2 | $100K | Buy |
+16,912
| New | +$104K | ﹤0.01% | 3546 |
|
Other funds holding SVA
O
VC
NAH
State Street's SVA Position: Q2 2024 in Review
State Street sold out of Sinovac Biotech, Ltd (SVA) in Q2 2024, closing a stake of 160,875 shares — an estimated $1.04M sold.
State Street first reported a position in SVA in Q2 2016 and held it in 28 quarters. The position peaked at $1.82M in Q4 2021. 26 funds tracked by Wall St. Rank hold SVA as of Q2 2024.
- State Street reported no remaining Sinovac Biotech, Ltd position as of Q2 2024 after selling out during the quarter.
- State Street sold 160,875 Sinovac Biotech, Ltd shares in Q2 2024, an estimated $1.04M.
- State Street first reported a position in Sinovac Biotech, Ltd in Q2 2016 and held it in 28 quarters.
- State Street's Sinovac Biotech, Ltd position peaked at $1.82M in Q4 2021.
- 26 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2024.
Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.